Gilead to file new CAR-T, setting up potential mid-2020 laun...

Gilead’s Kite unit plans to file its latest CAR-T therapy on the basis of a new study showing some impressive response rates in patients with relapsed or refractory mantle cell lymphoma.

Nearly half of lymphoma patients alive after Gilead's CAR-T ...

Nearly half of patients with advanced lymphoma treated with Gilead/Kite’s CAR-T therapy Yescarta were alive after three years, according to new figures unveiled this weekend.

Gilead's Descovy approved in HIV prophylaxis

The FDA has approved Gilead’s combination drug Descovy for HIV prophylaxis in the US, offering a way of cutting the risk of sexually acquired infection with an improved safety profile compa

Building cell therapy leadership in Europe

In these videos, Markwin Velders and Louis van de Wiel of Kite, a Gilead Company, provide a behind the scenes insight into the company’s European operations, including building a new manufactur

Delivering innovative therapies with close industry-NHS part...

It was a crucial moment when NHS England and the National Institute for Health and Care Excellence (NICE)

The top pharma companies by revenue 2018